Tirzepatide Clinical Pharmacology: Dual GIP/GLP-1 Agonism Across the SURPASS and SURMOUNT Programmes

Tirzepatide is a single synthetic peptide that activates both the GIP and GLP-1 incretin receptors. The dual-agonism framework distinguishes it from prior GLP-1-only agonists like semaglutide and positions it within the larger evolution of the incretin-class pipeline. This article walks through tirzepatide's clinical pharmacology, the SURPASS programme in type-2 diabetes, the SURMOUNT programme in obesity, and how the compound sits relative to semaglutide and retatrutide.

Dual agonism: the mechanism distinction

Tirzepatide is a 39-amino-acid synthetic peptide engineered as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The peptide backbone resembles GIP more closely than GLP-1; the engineered substitutions broaden the receptor binding spectrum to include GLP-1 while preserving GIP activity. The dual signalling enters incretin biology from a different angle than GLP-1-only agonism.

The GLP-1 arm produces the well-characterised effects: postprandial insulin secretion (glucose-dependent), suppression of inappropriate glucagon release, slowed gastric emptying, and central effects on satiety. These are the same effects that anchor semaglutide's clinical profile.

The GIP arm complements rather than duplicates GLP-1 effects. GIP signalling has distinct effects on adipose tissue (modulating lipid storage and lipolysis), on insulin secretion (potentiating beta-cell response in a complementary glucose-dependent manner), and on central nervous system satiety pathways through different neural circuitry than GLP-1. The combination produces metabolic effects that exceed what either single-receptor agonism achieves alone.

This is the mechanism reasoning for tirzepatide's larger clinical effect sizes. It is supported empirically by the SURPASS-2 head-to-head data — both arms received receptor-saturating doses of their respective compounds, and the dual-agonist arm produced larger HbA1c and body-weight effects.

SURPASS-2: the canonical head-to-head versus semaglutide

Frías and colleagues' 2021 NEJM paper ¹ reported SURPASS-2, the canonical head-to-head trial. Design: 1,879 adults with type-2 diabetes inadequately controlled on metformin randomised to weekly tirzepatide (5, 10, or 15 mg) or weekly semaglutide 1 mg. Duration: 40 weeks. Primary endpoint: HbA1c change from baseline.

Results: all three tirzepatide doses produced statistically and clinically larger HbA1c reductions than semaglutide 1 mg (tirzepatide 5/10/15 mg: -2.01%, -2.24%, -2.30% vs semaglutide 1 mg: -1.86%). Body weight: tirzepatide 5/10/15 mg produced mean reductions of 7.6, 9.3, and 11.2 kg respectively, versus 5.7 kg with semaglutide 1 mg. Adverse-event profiles were broadly similar across arms, with the gastrointestinal-tolerability signal typical of incretin-class compounds.

The interpretive caveat: SURPASS-2 used semaglutide 1 mg, the diabetes-approved dose at the time of the trial. The higher 2 mg and 2.4 mg semaglutide doses approved later for diabetes and obesity respectively were not tested in SURPASS-2. The head-to-head therefore reflects the T2DM treatment context with the semaglutide diabetes-dose specifically rather than a maximum-effective-dose comparison.

SURMOUNT-1: obesity without diabetes

Jastreboff and colleagues' 2022 NEJM paper ² reported SURMOUNT-1, the canonical tirzepatide obesity trial. Design: 2,539 adults with obesity (BMI ≥30) without type-2 diabetes randomised to weekly tirzepatide 5, 10, or 15 mg or placebo. Duration: 72 weeks. Primary endpoint: percent change in body weight from baseline.

Results: mean weight loss was 15.0%, 19.5%, and 20.9% across the three tirzepatide doses versus 3.1% with placebo. Secondary endpoints included substantial improvements in blood pressure, lipid profile, glycaemic control, and waist circumference. The 20.9% magnitude at the 15 mg dose is the largest weight-loss effect reported in a Phase 3 pharmacological obesity trial to date.

The comparison anchor is STEP-1 (Wilding 2021, NEJM, which reported 14.9% mean weight loss with semaglutide 2.4 mg over 68 weeks). SURMOUNT-1 and STEP-1 were not head-to-head, but the implicit comparison establishes a meaningful effect-size difference between the dual GIP/GLP-1 agonist and the GLP-1-only agonist at the doses each is currently used clinically for obesity.

SURPASS-3 and the MRI substudy: liver fat as a secondary outcome

Ludvik and colleagues' 2021 Lancet paper ³ reported SURPASS-3: tirzepatide versus insulin degludec in patients with type-2 diabetes inadequately controlled on metformin (with or without SGLT2 inhibitors). Tirzepatide outperformed insulin degludec on HbA1c reduction and on body weight (tirzepatide caused weight loss; insulin caused weight gain). The trial established tirzepatide as a viable pre-insulin treatment option in the T2DM treatment hierarchy.

The MRI substudy of SURPASS-3, reported by Gastaldelli and colleagues in 2022 (Lancet Diabetes Endocrinol) ⁴, quantified liver fat content via magnetic resonance over 52 weeks. Tirzepatide at 10 and 15 mg doses reduced liver fat content approximately 30-45% from baseline. Insulin degludec produced minimal change. The effect size is large enough to reclassify a substantial fraction of patients from NAFLD diagnostic thresholds to below.

This MRI substudy is the strongest single piece of evidence positioning tirzepatide as a candidate for the metabolic-dysfunction-associated steatotic liver disease (MASLD) research landscape. The liver fat effect is mechanistically connected to the visceral fat reduction observed in the broader SURPASS and SURMOUNT trials, but the dedicated MRI quantification makes it actionable for hepatic-endpoint research protocols specifically.

SURMOUNT-2: obesity with type-2 diabetes

Garvey and colleagues' 2023 Lancet paper ⁵ reported SURMOUNT-2: tirzepatide for obesity in patients who also have type-2 diabetes. Mean weight loss at the 10 and 15 mg doses was approximately 12.8% and 14.7% over 72 weeks — smaller than the SURMOUNT-1 magnitudes in obesity without diabetes.

The pattern is consistent across the incretin-class evidence base. Glycaemic-control populations show smaller weight-loss responses than otherwise-healthy obesity populations. The likely mechanism is that diabetes pathophysiology blunts some of the satiety and energy-expenditure effects that drive weight loss in non-diabetic populations. SURMOUNT-2 is the right reference for any research protocol enrolling obese-with-T2DM patients rather than the SURMOUNT-1 obesity-only population.

Positioning relative to semaglutide and retatrutide

The tirzepatide vs semaglutide question is partially answered by SURPASS-2 head-to-head and partially inferred from the trial programmes:

• For glycaemic control in T2DM at the doses each is used: tirzepatide has the head-to-head advantage (SURPASS-2)
• For weight loss in obesity without diabetes: tirzepatide has a substantially larger effect size in implicit comparison (SURMOUNT-1 vs STEP-1)
• For cardiovascular outcomes: semaglutide has the dedicated trial evidence (SUSTAIN-6 in T2DM, SELECT in obesity without diabetes). Tirzepatide's SURPASS-CVOT is still pending. See the GLP-1 cardiovascular outcomes deep-dive for the cardiovascular evidence landscape.
• For liver fat (MASLD-relevant research): tirzepatide has the MRI-quantified evidence (Gastaldelli 2022). Semaglutide's MASLD evidence is at an earlier stage in published literature.

The tirzepatide vs retatrutide question is mechanism-defined. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide is a triple GIP/GLP-1/glucagon agonist. Retatrutide is at an earlier Phase 2 stage; tirzepatide has the more mature Phase 3 evidence. For research protocols requiring currently-best-evidence weight-loss outcomes, tirzepatide is the closer reference. For protocols exploring the next-generation incretin pipeline, retatrutide is the more relevant compound.

What is settled vs. exploratory

Settled:

• HbA1c and weight-loss superiority over semaglutide 1 mg in T2DM (SURPASS-2)
• Largest published Phase 3 weight-loss magnitude in obesity without diabetes (SURMOUNT-1)
• Superiority over insulin degludec on HbA1c, weight, and glycaemic variability in T2DM (SURPASS-3)
• Substantial liver fat reduction at 10-15 mg doses (Gastaldelli 2022)
• Effect-size attenuation in obesity-with-T2DM versus obesity-without-T2DM (SURMOUNT-2)

Exploratory:

• Cardiovascular outcomes (SURPASS-CVOT pending)
• Direct head-to-head versus semaglutide 2.4 mg at the obesity-approved dose
• Long-term effects beyond the 72-week trial window
• Effects in non-T2DM non-obesity populations (e.g., MASLD-only, PCOS, sleep apnoea — research programmes are emerging)

For the broader tirzepatide vs semaglutide trial comparison see the Semaglutide vs Tirzepatide trials article. For the GLP-1 cardiovascular evidence landscape see the GLP-1 cardiovascular outcomes deep-dive. For research-protocol titration considerations see the GLP-1 titration protocols article.